Taken together, these studies support the hypothesis that CCL20-neutralising antibodies administered to patients with ischaemic heart disease have the potential to suppress the migration of CCR6+ IL-17A-producing γδT cells and improve prognosis. The gene discussed is IL17A; the disease is heart disorder.